Shuren: "We Don't Use Our People As Guinea Pigs In The U.S."
This article was originally published in The Gray Sheet
Executive Summary
CDRH Director Jeffrey Shuren specifically responded to the PwC report during the Jan. 19 press conference on the 510(k) reform plans.
You may also be interested in...
FDA Will Not Broadly Release Report Criticizing EU Oversight
The agency decided not to widely disseminate a report examining 12 high-risk devices that were approved in Europe, but were later found to be dangerous or ineffective.
Device Companies Look West, East, Anyplace But US
With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.
Device Companies Look West, East, Anyplace But US
With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.